For more than 10 years, CSL Behring has supported the World Federation of Hemophilia (WFH) to improve the diagnosis and treatment of bleeding disorders around the world.
In addition to its financial support for the organisation’s work, CSL Behring is a program sponsor and donor to the WFH’s Global Alliance for Progress (GAP) Program, a worldwide initiative seeking to save and improve the quality of life of people with bleeding disorders.
In May 2022, CSL Behring announced a ground-breaking new partnership with the World Federation of Hemophilia (WFH). Commencing in 2023, CSL Behring will donate 500 million international units (IUs) of coagulation factor therapy to the WFH, including product specifically manufactured for the purposes of being donated, creating consistent and reliable access to treatment for people living with bleeding disorders in more than 60 developing countries.
By manufacturing product specifically for the purposes of donation, the coagulation factor therapy will have a standard shelf life of three years, thus enabling greater access to these life-saving therapies for people around the world. The donated product will be delivered twice a year for five years.
CSL Behring also provides financial support for logistics costs and training programs designed to address unmet needs for people living with haemophilia in developing countries who are undiagnosed, untreated, or undertreated.
For more details on CSL’s patient and product impact as a result of the partnership see our detailed case study - Improving access in developing countries for patients with bleeding disorders - in section 9 of our Annual Report.